Publishing in Face of the COVID-19 Pandemic

Overview

Journal Int J Antimicrob Agents

Specialties Infectious Diseases
Pharmacology

Date 2020 Jul 18

PMID 32674930

Citations 8

Authors

Andreas Voss

Geoffrey Coombs

Serhat Unal

Raphael Saginur

Po-Ren Hsueh

Affiliations

Soon will be listed here.

Citing Articles

'Poly phenolic phytoceutical loaded nano-bilosomes for enhanced caco-2 cell permeability and SARS-CoV 2 antiviral activity': in-vitro and insilico studies.

Zakaria M, Abd El-Halim S, Beshay B, Zaki I, Abourehab M Drug Deliv. 2023; 30(1):2162157.

PMID: 36587813 PMC: 9809390. DOI: 10.1080/10717544.2022.2162157.

Delineating a potent antiviral activity of extract loaded nano-formulation against SARS-CoV-2: studies.

Mahmoud D, Ismail W, Moatasim Y, Kutkat O, ElMeshad A, Ezzat S J Drug Deliv Sci Technol. 2021; 66:102845.

PMID: 34539819 PMC: 8440321. DOI: 10.1016/j.jddst.2021.102845.

Open science saves lives: lessons from the COVID-19 pandemic.

Besancon L, Peiffer-Smadja N, Segalas C, Jiang H, Masuzzo P, Smout C BMC Med Res Methodol. 2021; 21(1):117.

PMID: 34090351 PMC: 8179078. DOI: 10.1186/s12874-021-01304-y.

The journey of antimalarial drugs against SARS-CoV-2: Review article.

Sarhan A, Ashour N, Al-Karmalawy A Inform Med Unlocked. 2021; 24:100604.

PMID: 34028468 PMC: 8132553. DOI: 10.1016/j.imu.2021.100604.

The Global COVID-19 Observatory and Resource Center for Childhood Cancer: A response for the pediatric oncology community by SIOP and St. Jude Global.

Moreira D, Sniderman E, Mukkada S, Chantada G, Bhakta N, Foster W Pediatr Blood Cancer. 2021; 68(5):e28962.

PMID: 33629507 PMC: 7994967. DOI: 10.1002/pbc.28962.

References

Gautret P, Lagier J, Parola P, Hoang V, Meddeb L, Mailhe M . RETRACTED: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020; 56(1):105949. PMC: 7102549. DOI: 10.1016/j.ijantimicag.2020.105949. View

Rosendaal F . Review of: "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Gautret et al 2010, DOI:10.1016/j.ijantimicag.2020.105949. Int J Antimicrob Agents. 2020; 56(1):106063. PMC: 7357515. DOI: 10.1016/j.ijantimicag.2020.106063. View

Machiels J, Bleeker-Rovers C, Ter Heine R, Rahamat-Langendoen J, de Mast Q, Ten Oever J . Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks?. Int J Antimicrob Agents. 2020; 56(1):106056. PMC: 7357524. DOI: 10.1016/j.ijantimicag.2020.106056. View